Localized Prostate Cancer—What the Medical Oncologist Needs to Know
Canadian Phase III randomised trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for localised prostate cancer, Int J Rad Oncol Biol Phys, 2004;60:15–23.
54. Hanks GE, Pajak TF, Porter A, et al., Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02, J Clin Oncol, 2003;21:3972–8.
55. Bolla M, de Reijke TM, Van Tienhoven G, et al., EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer, N Engl J Med, 2009;360(24):2516–27.
56. Messing EM, Manola J, Yao J, et al., Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy, Lancet Oncol, 2006;7(6):472–9.
57. Walsh PC, A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment, J Urol, 2001;166:508–15.
58. Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA, Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review, J Clin Oncol, 2007;25(31):4998–5008.
59. Schulman C, Debruyne M, Forster G, et al., 4-year follow-up results of a European prospective randomised trial on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-2N0M0 prostate cancer, Eur Urol, 2000;38:706–13.
60. Aus G, Abrahamsson PA, Ahlgren G, et al., Three-month neoadjuvant hormone therapy before radical prostatectomy: a 7-year follow up of a randomised trial, BJU Int, 2002;90:561–6.
61. Klotz LH, Goldenberg SL, Jewett MA, et al., Canadian Uro- Oncology Group. Long-term followup of a randomized trial of 0
versus 3 months of neoadjuvant androgen ablation before radical prostatectomy, J Urol, 2003;170(3):791–4.
62. McLeod DG, See WA, Klimberg I, et al., The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup, J Urol, 2006;176(1):75–80.
63. Petrylak DP, Tangen CM, Hussain MH, et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 2004;351(15):1513–20.
64. Tannock IF, de Wit R, Berry WR, et al., TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 2004;351(15):1502–12.
65. Levine GN, D’Amico AV, Berger P, et al., American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology, CA Cancer J Clin, 2010;60:194–201.
66. Saylor PJ, Smith MR, Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer, J Natl Compr Canc Netw, 2010;8(2):211–23.
67. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS, Risk of fracture after androgen deprivation for prostate cancer, N Engl J Med, 2005;352:154–64.
68. Diamond TH, Winters J, Smith A, et al., The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebocontrolled crossover study, Cancer, 2001;92:1444–50.
69. Israeli RS, Rosenberg SJ, Saltzstein DR, et al., The effect of
zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy, Clin Genitourin Cancer, 2007;5:271–7.
70. Smith MR, Eastham J, Gleason DM, et al., Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer, J Urol, 2003;169:2008–12.
71. Smith MR, McGovern FJ, Zietman AL, et al., Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer, N Engl J Med, 2001;345:948–55.
72. Ryan CW, Huo D, Demers LM, et al., Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer, J Urol, 2006;176:972–8.
73. Greenspan SL, Nelson JB, Trump DL, et al., Effect of once- weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial, Ann Intern Med, 2007;146:416–24.
74. Greenspan SL, Nelson JB, Trump DL, et al., Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy, J Clin Oncol, 2008;26:4426–34.
75. Michaelson MD, Kaufman DS, Lee H, et al., Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer, J Clin Oncol, 2007;25:1038–42.
76. Amir E, Tannock IF, Prostate cancer: androgen deprivation therapy and bone loss, Nat Rev Urol, 2009;6(12):642–4.
77. Smith MR, Egerdie B, Hernández Toriz N, et al., Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer, N Engl J Med, 2009;361(8):745–55.
78. Smith MR, Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma, Cancer, 2003;97 (3 Suppl.):789–95.
US ONCOLOGY & HEMATOLOGY
57
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84